Robert Arch, OncoSec Medical CEO
OncoSec reports flop for IL-12/Keytruda combo in what may be final blow
A six-year trial testing the combination of OncoSec Medical’s IL-12 therapy with Merck’s Keytruda has ended in failure.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.